Pharmacogenetic Tests for Antipsychotic-Induced Weight Gain

E. O. Zhuravleva; N. Yu. Vel’ts; I. I. Snegireva; G. V. Kutekhova; R. N. Alyautdin

doi:10.1007/s11094-019-02059-z

Pharmacogenetic Tests for Antipsychotic-Induced Weight Gain

Авторы: Zhuravleva E.O.¹, Vel’ts N.Y.¹, Snegireva I.I.¹, Kutekhova G.V.¹, Alyautdin R.N.¹
Учреждения:
1. Ministry of Health of the Russian Federation, Scientific Center for Expert Evaluation of Medicinal Products
Выпуск: Том 53, № 7 (2019)
Страницы: 668-671
Раздел: Discussion
URL: https://ogarev-online.ru/0091-150X/article/view/245937
DOI: https://doi.org/10.1007/s11094-019-02059-z
ID: 245937

Цитировать

Полный текст

Открытый доступ
Доступ закрыт

Доступ предоставлен
Доступ закрыт

Только для подписчиков

Аннотация
Об авторах
Список литературы
Дополнительные файлы
Статистика

Аннотация

Second-generation antipsychotic substances, as compared with first-generation antipsychotics, are more effective in relation to psychotic symptoms and have significantly lower potential for developing extrapyramidal impairments such as parkinsonism and late dyskinesia. However, use of these agents is associated with significant weight gain in patients. Advances in the pharmacogenetics of antipsychotic-induced weight gain are analyzed here.